INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for alleged securities fraud and unlawful business practices following disappointing trial results [2][3]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Altimmune and its officers engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Altimmune securities during the Class Period have until October 6, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Trial Results and Market Reaction - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [3]. - The trial results showed a positive trend in fibrosis improvement, but a higher-than-expected placebo response led to the lack of statistical significance [3]. - Following the announcement, Altimmune's stock price fell by $4.10 per share, or 53.2%, closing at $3.61 per share [4].